Eli Lilly halts COVID-19 antibody treatment trial over safety issues
Category: #headlines  By Nikita Chaurasia  Date: 2020-10-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly halts COVID-19 antibody treatment trial over safety issues

 

  • The announcement comes along the heels of a sudden spike in the number of coronavirus cases across U.S.
  • Eli Lilly’s shares dropped by about 3% after it halted the COVID-19 antibody trials.

Eli Lilly and Company, an American pharmaceutical company, has reportedly announced that it has paused its government sponsored COVID-19 antibody treatment trial over safety concerns. Sources close to the matter stated that the announcement comes along the heels of a sudden spike in the number of coronavirus cases across United States.

For the record, Eli Lilly’s COVID-19 antibody study will focus on the benefits of the therapy on various patients suffering from the novel coronavirus. Besides the potential antibody, each participant has reportedly also received an experimental drug called remdesivir which is commonly used to treat COVID-19 patients.

It is to be noted that the company had recently requested for an EUA (emergency use authorization) for its antibody LY-CoV555 from the U.S. Food & Drug Association (FDA). However, the exact safety concerns which halted the trials remain unclear, sources claimed.

Molly McCully, a spokesperson from Eli Lilly mentioned in a comment that the ACTIV-3 data safety monitoring board (DSMB) suggested the company to halt the trials. She further added that the Eli Lilly supported the decision made by the independent DSMB for the wellbeing of the study participants.

According to industry experts, such pauses during large scale clinical trials are not an uncommon instance and the decline in the volunteer’s health is not necessarily due to the vaccine or an experimental drug. In fact, such study halts enable scientific experts to review the data generated during the trials.

Eli Lilly’s shares dropped by about 3% after it halted the COVID-19 antibody trials, cited sources with relevant information.

In other news, another American pharmaceutical company, Johnson & Johnson, had reportedly paused its study for COVID-19 antibody candidate after one of the trial participants witnessed an unexpected illness.

Source- https://www.aljazeera.com/economy/2020/10/13/eli-lilly-pauses-covid-19-antibody-trial-due-to-safety-concern

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Facebook sued for failing to protect data in Cambridge Analytica breach
Facebook sued for failing to protect data in Cambridge Analytica breach
By Nikita Chaurasia

  The group taking the social media giant to court is ‘Facebook You Owe Us’. Facebook claims to have not received any documents pertaining to the lawsuit. American social media conglomerate Facebook Inc. has reportedly been sue...

Sony witnesses high demand for Play Station 5 through preorders
Sony witnesses high demand for Play Station 5 through preorders
By Nikita Chaurasia

Japanese multinational conglomerate Sony Corporation has reportedly witnessed a high demand for its PlayStation 5 (PS5) console with the pre-orders coming in at an unexpected pace. Market analysts claim that the company intends to lead the competiti...

London’s gearing up to deliver Covid-19 vaccine as early as next week
London’s gearing up to deliver Covid-19 vaccine as early as next week
By Nikita Chaurasia

The George Eliot Hospital NHS Trust, Warwickshire, is likely to receive the first batches of AstraZeneca’s and Oxford’s coronavirus vaccine on 2nd November. The revelation comes along the heels of directive to George Eliot Hospital NHS T...